Managing depression in Parkinson’s patients risk factors and clinical pearls.pdfVIP

Managing depression in Parkinson’s patients risk factors and clinical pearls.pdf

  1. 1、本文档共8页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  5. 5、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  6. 6、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  7. 7、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  8. 8、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Managing depression in Parkinson’s patients risk factors and clinical pearls

329ISSN 1758-2024Neurodegen. Dis. Manage. (2014) 4(4), 329–336 part of 10.2217/NMT.14.31 ? 2014 Future Medicine Ltd REVIEW Managing depression in Parkinson’s patients: risk factors and clinical pearls Rachel Biemiller1 Irene Hegeman Richard*,1 1University of Rochester, Rochester, NY, USA *Author for correspondence: Tel.: +1 585 341 7500; Fax: +1 585 276 1870; Irene_richard@URMC. Practice points Depression Parkinson’s disease ● Depressed mood is a stronger indicator than anhedonia for depression. ● Apathy may be a core feature of Parkinson’s disease (PD) and does not necessarily indicate depression. ● Negative emotions are more likely to indicate depression than apathy. ● PD symptoms and depression symptoms can be similar. ● Mood symptoms can fluctuate with motor symptoms. ● Depression and anxiety frequently overlap. Diagnosis ● Use an inclusive approach. ● Evaluate in the ‘on’ state. ● Get input from care partner. ● Use depressed mood as a core symptom. ● Use a rating scale to screen for depression or to rate severity of depressive symptoms. Treatment ● Pramipexole – use if mood fluctuates with motor symptoms. ● Tricyclic antidepressants – effective but poorly tolerated due to side effects. ● Selective serotonin/noreinephrine reuptake inhibitors – currently first line therapy. ● Use cognitive behavioral therapy alone or in addition to pharmacotherapy. Future research needs ● A better understanding of the role of anxiety in depression in PD is needed. ● More research into treatment options for refractory depression and anxiety. ● The role of surgical and other non-pharmacologic interventions should be further investigated. For reprint orders, please contact: reprints@ 330 Neurodegen. Dis. Manage. (2014) 4(4) Review Biemiller Richard future science group Parkinson’s disease (PD) is a neurodegenerative process, which typically affects older adults. Over the next few decades, this population is expected to increase. A study by

您可能关注的文档

文档评论(0)

l215322 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档